ZYPREXA OLANZAPINE 5MG TABLETS 28S

Indications and dosage

1. Schizophrenia

PO

• 5-10 mg/day initially; if necessary, may be titrated upward in increments of 5 mg/day at intervals >1 week
• Maintenance: 10-20 mg/day; not to exceed 20 mg/day

 

2. Bipolar Mania

Indicated for acute/maintenance treatment of manic or mixed episodes associated with bipolar 1 disorder; may be used adjunctively to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar disorder

Monotherapy: 10-15 mg/day PO initially; may be titrated upward in increments of 5 mg/day at intervals >24 hr

Adjunct to lithium or valproate: 10 mg/day PO initially

Maintenance: 5-20 mg/day PO; not to exceed 20 mg/day

3. Bipolar Depression

Indicated for depressive episodes associated with bipolar I disorder in combination with fluoxetine

5 mg PO in evening; adjusted to range of 5-12.5 mg/day

4. Chemotherapy Associated Nausea or Vomiting (Off-label)

Off-label use for prevention of chemotherapy associated nausea or vomiting in combination with 5-HT3 antagonist and dexamethasone (N Engl J Med 2016;375[2]:134-42)

Breakthrough nausea and vomiting: 5-10 mg PO qDay for 3 days, when not used for acute and delayed emesis prevention

Acute and delayed emesis prevention

• Off-label use for prevention of chemotherapy associated nausea or vomiting in combination with 5-HT3 antagonist and dexamethasone
• In combination with dexamethasone and a 5-HT3 antagonist (eg, palonosetron, aprepitant)
• High emetic risk IV chemotherapy: 10 mg PO the day of chemotherapy (day 1), followed by 10 mg PO qDay (days 2-4)
• Moderate emetic risk IV chemotherapy: 10 mg PO the day of chemotherapy (day 1), followed by 10 mg PO qDay (days 2-3)

 

???? PEDIATRICS

1. Bipolar I Disorder (Manic or Mixed Episodes)

<13 years: Safety and efficacy not established

13-17 years: 2.5-5 mg/day PO initially; target dosage, 10 mg/day; adjust by increments/decrements of 2.5-5 mg; dosage range, 2.5-20 mg/day

2. Schizophrenia

<13 years: Safety and efficacy not established

13-17 years: 2.5-5 mg/day PO initially; target dosage, 10 mg/day; adjust by increments/decrements of 2.5-5 mg; dosage range, 2.5-20 mg/day

3. Bipolar Depression

Indicated for depressive episodes associated with bipolar I disorder in combination with fluoxetine

<10 years: Safety and efficacy not established

10-17 years: 2.5 mg PO qPM and fluoxetine 20 mg PO qPM initially; dosage adjustments, if indicated, should be made to individual components according to efficacy and tolerability

Safety of coadministered doses greater than olanzapine 12 mg with fluoxetine 50 mg have not been in pediatric clinical studies

4. Stuttering (Off-label)

?12 years: 1.25 mg PO at bedtime for 4 weeks, then 2.5 mg at bedtime

 

GERIATRIC

INTERACTIONS

Click on here for interactions.

 

ADVERSE EFFECTS

Adverse Effects